189279-58-1

Basic information

• Product Name: ABT-492
• Synonyms: ABT-492;1-(6-Amino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxy-1-azetidinyl)-4-oxo-3-quinolinecarboxylic acid;Delafloxacin;Delafloxacinum;3-Quinolinecarboxylic acid, 1-(6-aMino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxy-1-azetidinyl)-4-oxo-;WQ3034;ABT-492(WQ-3034);ABT492/ABT-492
• CAS NO: 189279-58-1
• Molecular Formula: C₁₈H₁₂ClF₃N₄O₄
• Molecular Weight: 440.7604896
• Product Categories: API
• Mol File: 189279-58-1.mol
• Article Data: 10

Chemical Properties

• Melting Point: 238-241℃
• Boiling Point: 698.5 °C at 760 mmHg
• Flash Point: 376.2 °C
• Appearance: /
• Density: 1.796
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Very Slightly, Heated, Sonicated)
• PKA: 5.49±0.50(Predicted)
• CAS DataBase Reference: ABT-492(CAS DataBase Reference)
• NIST Chemistry Reference: ABT-492(189279-58-1)
• EPA Substance Registry System: ABT-492(189279-58-1)

Safety Data

• Hazardous Substances Data: 189279-58-1(Hazardous Substances Data)

Usage

Uses

Delafloxacin is a potent agent and broad-spectrum anionic fluoroquinolone against Streptococcus pneumoniae and diverse group of pathogens.

Biochem/physiol Actions

Delafloxacin is a fluoroquinolone antibiotic active against both Gram-negative and Gram-positive bacteria such as MRSA. Delafloxacin targets both DNA gyrase and topoisomerase IV, inhibiting DNA synthesis. Unlike most fluoroquinolones, delafloxacin is weakly acidic, which increases its potency in an acidic environments such as those existing in inflammatory cells and in skin and soft tissue infections. Delafloxacin shows good activity against most fluoroquinolone-resistant strains.

Upstream product

• 189279-53-6 1-(6-amino-3,5-difluoro-2-pyridinyl)-8-chloro-6,7-difluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid 
• 18621-18-6 azetion-3-ol hydrochloride 
• 442526-91-2 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-isobutyryloxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 
• 101987-86-4 ethyl β-(3-chloro-2,4,5-trifluorophenyl)-β-oxopropionate 
• 189279-51-4 1-(6-amino-3,5-difluoro-2-pyridyl)-8-chloro-6-fluoro-1,4-dihydro-7-fluoro-4-oxo-3-quinolinecarboxylic acid ethyl ester 
• 875712-90-6 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-isobutyryloxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 
• 120-94-5 1-Methylpyrrolidine 
• 189281-08-1 ethyl 5-amino-1-(6-amino-3,5-difluoropyridin-2-yl)-6,7,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate 
• 98349-24-7 ethyl 2,4,5-trifluorobenzoylacetate 

Downstream Products

• 352458-37-8 1-(6-amino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxy-1-azetidinyl)-4-oxo-3-quinolinecarboxylic acid 1-deoxy-1-(methylamino)-D-glucitol 

Relevant articles and documents

Refining method of ciprofloxacin and meglumine hydrochloride thereof

The invention provides a preparation process of ciprofloxacin and meglumine thereof. The intermediate product DLSX07 is stirred at Branson ° C. 20% minutes and then sonicated until the solution is cloudy, stirred at room temperature for a period 30s, stirred at room temperature 3h, cooled and slowly added to distilled water, and filtered through suction filtration and filter cake vacuum drying to obtain a pale yellow powder, and 4% the KOH mixture is subjected to ultrasonic treatment 40 - 50 °C. 1. The process is performed by stirring 5h. NCS .t. The solution is cloudy. LC-MS / MS detection powder is deltafloxacin, distilled water is added, and meglumine is mixed to obtain a deltafloxacin meglumine salt. By optimizing the preparation process, the use of the organic solvent is reduced, the reaction time is shortened, and the ice bath and the addition of the interface carrier material contribute to the improvement of the yield.

Preparation of deller floxacin and intermediate thereof

The invention relates to preparation of deller floxacin and an intermediate thereof. According to the preparation method of the deller floxacin, the purity of an intermediate compound, a compound A-3and a compound W-4 is limited to be more than 99.0 perce

A method for preparing high-purity delafloxacin

The invention belongs to the technical field of a high purity delafloxacin preparation method. The high purity delafloxacin preparation method is as follows: a compound shown as formula 14 is hydrolyzed into a salt, a purified solid salt is obtained by solid-liquid separation, and then the purified solid salt is acidified to obtain delafloxacin. The delafloxacin prepared by synthesis methods in the prior art is low in purity, and needs to be further refined; according to the high purity delafloxacin preparation method, a delafloxacin ester derivative is hydrolyzed into a salt, after separation, the salt is acidified for effective removal of impurities, so that the product delafloxacin can reach a high purity (more than 99.5%), and can meet the subsequent preparation requirements; by the high purity delafloxacin preparation method, the objective of refinement can be achieved in the reaction route, a further purification process is omitted, and the operation efficiency and the total yield are improved.